Boston Scientific Corporation (NYSE:BSX) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET
Company Participants
Mike Mahoney - Chairman & CEO
Dan Brennan - EVP & CFO
Dr. Ken Stein - SVP & Global CMO
Lauren Tengler - VP, IR
Conference Call Participants
Robbie Marcus - J.P. Morgan
Joanne Wuensch - Citibank
Rick Wise - Stifel
Vijay Kumar - Evercore ISI
Larry Biegelsen - Wells Fargo Securities
Travis Steed - Bank of America Securities
Danielle Antalffy - UBS
Matt Taylor - Jefferies
Josh Jennings - TD Cowen
Chris Pasquale - Nephron Research
Mike Polark - Wolfe Research
Matthew O'Brien - Piper Sandler
Operator
Good day, and welcome to the Boston Scientific Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please also note, this event is being recorded.
I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Lauren Tengler
Thank you, Costas. Welcome everyone, and thanks for joining us today. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer, and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q2 2023 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release, as well as reconciliations on the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financials & Filings. The duration of this morning's call will be approximately one hour. Mike and Dan will provide comments on Q3 performance, as well as the outlook for our business, including Q4 and full-year 2023 guidance. Then we'll take your questions. During today's Q&A session, Mike, and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, operational revenue growth excludes the impact of foreign currency fluctuations, and organic revenue growth further excludes acquisitions and divestitures for which there are less than a full period of comparable net sales. Relevant acquisitions and divestitures excluded for organic growth are Baylis Medical, which closed on February 14, 2022, the majority stake investment in Acotec Scientific, and Apollo Endosurgery, which closed in February and April of this year, respectively. Divestitures include the endoscopy pathology business, which closed April of this year. Please note that we have elected to consolidate Acotec results on a one quarter lag, which had been included in our Q3 reported and adjusted results. Guidance excludes the previously announced agreement to acquire Relievant Medsystems, which is expected to close in the first half of 2024, subject to customary closing conditions. For more information, please refer to our financial and operating highlights deck, which may be found on our Investor Relations website.